Document Type : Original Article


1 Department of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

2 Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

3 Center for Research of Endemic Parasites of Iran, Tehran University of Medical Sciences, Tehran, Iran

4 Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran

5 Department of Biotechnology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

6 Applied Biotechnology Research Center, Baqiyatallah University of Medical Science, Tehran, Iran

7 Zoonosis Research Center, Tehran University of Medical Sciences, Tehran, Iran


Zoonotic cutaneous leishmaniasis caused by Leishmania major is a most common type of vector-borne disease in Iran. The pentavalent antimonial drugs have been used in the treatment of cutaneous leishmaniasis for a long time, but drug resistance and some of serious side effects have been reported. Thus, discovery and development of new therapeutic candidates are needed. The CM11 peptide is one of these peptides that its anti-bacterial activity has been proven. This peptide is a short cecropin–melittin hybrid peptide obtained through a sequence combination approach. The aim of this study was to evaluate in vitro anti-leishmanial activity of CM11 peptide against amastigote forms of Leishmania major. In this study, amastigote forms of Iranian strain of L. major (MRHO/IR/75/ER) were cultured in the presence of different concentrations of meglumine antimoniate (Glucantime®) to find the most appropriate in vitro concentration of Glucantime® against L. major amastigotes. Then, the anti-leishmanial activities of various concentrations of CM11 peptide (8, 16, 32 and 64 µM) were evaluated for 24, 48 and 72 hr by DAPI staining. In addition, MTT assay was used to determine the cytotoxic effects of CM11 peptide on murine fibroblast cell line. The results showed that CM11 peptide has antimicrobial activity against Iranian isolate of L. major in the laboratory conditions. It seems that the CM11 peptide has significant potential to be used as a new anti-leishmanial agent.


Main Subjects


    1. Brito ME, Andrade MS, Dantas-Torres F, et al. Cutaneous leishmaniasis in northeastern Brazil: A critical appraisal of studies conducted in State of Pernambuco. Rev Soc Bras Med Trop 2012; 45(4): 425-429.
    2. Aoun K, Bouratbine A. Cutaneous leishmaniasis in North Africa: A review. Parasite 2014; 21:14. doi: 10.1051/parasite/2014014.
    3. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PloS One 2012; 7(5): e35671. 0035671.
    4. Mohebali M, Javadian E, Yaghoobi Ershadi M, et al. Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran. East Mediterr Health J 2004;10 (4-5): 591-599.
    5. Shirzadi M, Esfahani S, Mohebali M, et al. Epidemiological status of leishmaniasis in the Islamic Republic of Iran, 1983-2012. East Mediterr Health J 2015; 21(10): 736-742.
    6. Murray HW, Berman JD, Davies CR, et al. Advances in leishmaniasis. Lancet 2005; 366(9496): 1561-1577.
    7. Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007; 103(1): 33-40.
    8. Hadighi R, Mohebali M, Boucher P, et al. Un-responsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006; 3(5): e162.
    9. Mittal MK, Rai S, Gupta S, et al. Characterization of natural antimony resistance in Leishmania donovani isolates. Am J TropMed Hyg 2007; 76(4): 681-688.
    10. Zarean M, Maraghi S, Hajjaran H, et al. Comparison of proteome profiling of two sensitive and resistant field Iranian isolates of Leishmania major to Glucantime® by 2-dimensional electrophoresis. Iran J Parasitol 2015; 10(1): 19-29.
    11. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24(12): 1551-1557.
    12. Cotter PD, Hill C, Ross RP. Bacteriocins: Developing innate immunity for food. Nat Rev Microbiol 2005; 3(10): 777-788.
    13. Thevissen K, Kristensen HH, Thomma BP, et al. Therapeutic potential of antifungal plant and insect defensins. Drug Discov Today2007; 12(21-22): 966-971.
    14. Slocinska M, Marciniak P, Rosinski G. Insects antiviral and anticancer peptides: New leads for the future? Protein Pept Lett 2008; 15(6): 578-585.
    15. Zhang L, Falla TJ. Host defense peptides for use as potential therapeutics. Curr Opin Investig Drugs 2009; 10(2): 164-171.
    16. Diaz-Achirica P, Ubach J, Guinea A, et al. The plasma membrane of Leishmania donovani promastigotes is the main target for CA (1–8) M (1–18), a synthetic cecropin A–melittin hybrid peptide. Biochem J 1998; 330(1): 453-460.
    17. Luque-Ortega JR, Hof WV, Veerman EC, et al. Human antimicrobial peptide histatin 5 is a cell-penetrating peptide targeting mitochondrial ATP synthesis in Leishmania. FASEB J 2008; 22(6): 1817-1828.
    18. Vouldoukis I, Shai Y, Nicolas P, et al. Broad spectrum antibiotic activity of skin-PYY. FEBS Lett 1996; 380(3): 237-240.
    19. Ferre R, Badosa E, Feliu L, et al. Inhibition of plant-pathogenic bacteria by short synthetic cecropin A-melittin hybrid peptides. Appl Environ Microbiol 2006; 72(5): 3302-3308.
    20. Mohammadi-Azad Z, Moravej H, Fasihi-Ramandi M, et al. In vitro synergistic effects of a short cationic peptide and clinically used antibiotics against drug-resistant isolates of Brucella melitensis. J Med Microbiol 2017; 66(7): 919-926.
    21. Badosa E, Ferre R, Planas M, et al. A library of linear undecapeptides with bactericidal activity against phytopathogenic bacteria. Peptides 2007; 28(12): 2276-2285.
    22. Mohebali M, Rezayat M, Gilani K, et al. Nanosilver in the treatment of localized cutaneous leishmaniasis caused by Leishmania major (MRHO/IR/75/ER): An in vitro and in vivo study. Daru J Pharm Sci 2009; 17(4):285-289.
    23. Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27(5): 305-318.
    24. Ouellette M, Papadopoulou B. Mechanisms of drug resistance in Leishmania. Parasitol Today 1993; 9(5): 150-153.
    25. Handman E, Noormohammadi AH, Curtis JM, et al. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine 2000; 18(26): 3011-3017.
    26. Stober CB, Lange UG, Roberts MT, et al. From genome to vaccines for leishmaniasis: Screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 2006; 24(14): 2602-2616.
    27. Singh N, Kumar M, Singh RK. Leishmaniasis: Current status of available drugs and new potential drug targets. Asian Pac J Trop Med 2012; 5(6): 485-497.
    28. Cobb SL, Denny PW. Antimicrobial peptides for leishmaniasis. Curr Opin Investig Drugs 2010; 11(8): 868-875.
    29. Montesinos E. Antimicrobial peptides and plant disease control. FEMS Microbiol Lett 2007; 270(1): 1-11.
    30. Montesinos E, Bardaji E. Synthetic antimicrobial peptides as agricultural pesticides for plant-disease control. Chem Biodivers 2008; 5(7): 1225-1237.
    31. Marcos JF, Munoz A, Perez-Paya E, et al. Identification and rational design of novel antimicrobial peptides for plant protection. Annu Rev Phytopathol 2008; 46: 273-301.
    32. Moghaddam MM, Abolhassani F, Babavalian H, et al. Comparison of in vitro antibacterial activities of two cationic peptides CM15 and CM11 against five pathogenic bacteria: Pseudomonas aeruginosa, Staphylococcus aureus, Vibrio cholerae, Acinetobacter baumannii, and Escherichia coli. Probiotics Antimicrob Proteins 2012; 4(2): 133-139.
    33. Moghaddam MM, Aghamollaei H, Kooshki H, et al. The development of antimicrobial peptides as an approach to prevention of antibiotic resistance. Rev Med Microbiol 2015; 26(3): 98-110.
    34. Marr AK, Gooderham WJ, Hancock RE. Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. Curr Opin Pharmacol 2006; 6(5): 468-472.
    35. Poorrajab F, Ardestani SK, Emami S, et al. Nitroimidazolyl-1, 3, 4-thiadiazole-based anti-leishmanial agents: Synthesis and in vitro biological evaluation. Eur J Med Chem 2009; 44(4): 1758-1762.
    36. Ghaffarifar F. Leishmania major: In vitro and in vivo anti-leishmanial effect of cantharidin. Exp Parasitol 2010;126(2): 126-129.
    37. Dolis D, Moreau C, Zachowski A, et al. Amino-phospholipid translocase and proteins involved in transmembrane phospholipid traffic. Biophys Chem 1997; 68(1-3): 221-231.
    38. Rudenko SV, Wajdi KJM. Modulatory effect of peptide structure and equilibration conditions of cells on peptide-induced hemolysis. J VNKarazin Kharkiv Natl Univ Ser Biol 2005; 709(1-2):139-146.